Last checked at 5 Jun 2018 12:47
Destiny Pharma plc
("Destiny Pharma" or "the Company")
Director/PDMR Shareholding
Brighton, United Kingdom - 5 June 2018 - Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel anti-microbial drugs, which address the global problem of anti-microbial resistance (AMR), announces that Sir Nigel Rudd, Non-Executive Chairman of the Company, has today notified the Company that, on 4 June 2018, he and his wife have purchased a total of 74,900 ordinary shares of 1 pence each in the Company ("Ordinary Shares") at a price of 110.04 pence per share.
Following this notification, Sir Nigel Rudd, together with connected parties, has a beneficial holding of 1,229,900 Ordinary Shares (which represents 2.82 per cent. of the issued share capital of the Company).
The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.
1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
a)
| Name
| Sir Nigel Rudd | ||||
2 | Reason for the notification | |||||
a)
| Position/status | Non-Executive Chairman | ||||
b) | Initial notification / Amendment | Initial Notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a)
| Name
| Destiny Pharma plc | ||||
b)
| LEI
| 213800O9WH9Z38EHAC95 | ||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a)
| Description of the financial instrument, type of instrument
Identification code: | Ordinary shares of 1 pence each ISIN: GB00BDHSP575 | ||||
b)
| Nature of the transaction
| Purchase of Ordinary Shares into ISA | ||||
c)
| Price(s) and volume(s) |
| ||||
d)
| Aggregated information
| N/A | ||||
e)
| Date of the transaction | 4 June 2018 | ||||
f) | Place of the transaction | London Stock Exchange, AIM | ||||
1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
a)
| Name
| Lady Lesley Rudd | ||||
2 | Reason for the notification | |||||
a)
| Position/status | Person closely associated to Sir Nigel Rudd, Non-Executive Chairman | ||||
b) | Initial notification / Amendment | Initial Notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a)
| Name
| Destiny Pharma plc | ||||
b)
| LEI
| 213800O9WH9Z38EHAC95 | ||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a)
| Description of the financial instrument, type of instrument
Identification code: | Ordinary shares of 1 pence each ISIN: GB00BDHSP575 | ||||
b)
| Nature of the transaction
| Purchase of Ordinary Shares into ISA | ||||
c)
| Price(s) and volume(s) |
| ||||
d)
| Aggregated information | N/A | ||||
e)
| Date of the transaction | 4 June 2018 | ||||
f) | Place of the transaction | London Stock Exchange, AIM | ||||
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
Simon Sacerdoti, CFO
pressoffice@destinypharma.com
+44 (0)1273 704 440
FTI Consulting
Simon Conway / Victoria Foster Mitchell
destinypharma@fticonsulting.com
+44 (0) 20 3727 1000
Cantor Fitzgerald Europe (Nominated Adviser and Joint Broker)
Philip Davies / Will Goode, Corporate Finance
Andrew Keith, Healthcare Equity Sales
+44 (0)20 7894 7000
finnCap Ltd (Joint Broker)
Geoff Nash /Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0)20 7220 0500
About Destiny Pharma
Destiny Pharma is an established, clinical stage, innovative biotechnology company focused on the development of novel medicines that represent a new approach to the treatment of infectious disease. These potential new medicines are being developed to address the need for new drugs for the prevention and treatment of life-threatening infections caused by antibiotic-resistant bacteria, often referred to as "superbugs". Tackling anti-microbial resistance has become a global imperative recognised by the World Health Organisation (WHO) and the United Nations, as well as the G7 and the G20 countries. For further information, please visit https://www.destinypharma.com